乙克洛维尔作为重症慢性活跃爱斯坦-巴尔病毒的新疗法
Mary Therese Thomas1, Philip Mardock1, Kedareeshwar S Arukala1
1Internal Medicine, Grand Strand Medical Center, Myrtle Beach, USA.
Cureus
|July 11, 2024
概括
长期活跃的爱斯坦-巴尔病毒 (CAEBV) 可以导致急性肝炎和. 阿西克洛维尔在治疗一位老年妇女严重CAEBV病例方面表现有前途.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 爱斯坦-巴尔病毒 (EBV) 是一种常见的病原体,具有典型的亚临床初级感染.
- 由T细胞增殖驱动的EBV的慢性持续性可能导致严重的并发症,如慢性活性EBV (CAEBV).
- 由于CAEBV引起的急性肝炎是一种罕见的临床表现.
研究的目的:
- 报告一种罕见的急性肝炎和由CAEBV引起的副次性炎病例.
- 描述这种严重的EBV表现的临床表现和管理.
- 为了评估在耐火CAEBV病例中阿西克洛维尔的疗效.
主要方法:
- 一个81岁的妇女的病例报告,患有急性肝炎和.
- 诊断工作显示EBV感染与肝损伤,血小板减少和.
- 由于耐火性疾病而接受阿西克洛维尔治疗,尽管接受了支持性护理.
主要成果:
- 患者表现出严重的症状,包括腹痛,恶心,吐,血小板缺血症恶化,横胺炎和急性.
- 对于EBV的标准支持性护理是无效的,需要密集护理和非传统治疗.
- 乙克洛维尔治疗导致完全康复,没有后果.
结论:
- 急性肝炎和可以呈现CAEBV的表现.
- 耐火CAEBV病例可能需要新的治疗方法.
- 阿西克洛维尔证明了作为严重的CAEBV与肝脏参与的治疗选择的潜力.
相关概念视频
Retrovirus Life Cycles
45.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Antiepileptic Drugs: Potassium Channel Activators
165
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
165
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
284
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
284


